Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Radiology · Papillary Thyroid Carcinoma

Diagnosing PTC and Understanding Your Pathology Report

At a Glance

Papillary thyroid cancer is evaluated through ultrasound, needle biopsy, and, when surgery is done, a detailed pathology report. Bethesda results, tumor features, margins, lymph nodes, and selected gene changes help doctors estimate risk and plan follow-up.

The path from discovering a thyroid nodule to a final diagnosis involves several distinct steps. This journey typically begins with imaging, moves to a needle biopsy, and—if surgery is performed—culminates in a detailed pathology report. Understanding these steps allows you to audit your own medical records and engage more deeply with your care team.

The First Look: Ultrasound Features

Ultrasound is the primary tool used to decide if a thyroid nodule needs further investigation [1]. Radiologists look for specific highly suspicious features that are more common in Papillary Thyroid Carcinoma (PTC). These include:

  • Hypoechoic appearance: The nodule appears darker than the surrounding thyroid tissue [2].
  • Irregular or lobulated margins: The edges of the nodule are jagged rather than smooth [2].
  • Microcalcifications: Tiny, bright white spots (also called punctate echogenic foci) inside the nodule [2].
  • Taller-than-wide shape: The nodule is taller in the vertical plane than it is wide.

Any suspicious lymph nodes in the neck will also be evaluated separately during this scan.

The Needle Biopsy: The Bethesda System

If a nodule looks suspicious, a Fine Needle Aspiration (FNA) is often performed. The results are reported using the Bethesda System, which categorizes the risk that a nodule is cancerous [3]:

  • Bethesda I (Nondiagnostic): Not enough cells were collected; the test usually needs to be repeated [3].
  • Bethesda II (Benign): Very low risk of cancer [4].
  • Bethesda III or IV (Indeterminate): The cells look unusual, but it’s not clear if they are cancer. Molecular testing or a diagnostic lobectomy (removing half the thyroid) may be recommended [5].
  • Bethesda V (Suspicious for Malignancy): High risk of cancer (estimated ranges vary around 85%, depending on institution and whether NIFTP is counted), generally warranting a surgical-planning discussion [4].
  • Bethesda VI (Malignant): Very high certainty of cancer, typically PTC [4].

Decoding Histologic Variants

Not all PTC is the same. Under a microscope, pathologists identify “variants” based on how the cells are arranged.

  • Classic Variant: The most common form, typically following a slow, predictable course [6].
  • Aggressive Variants: Some patterns, such as Tall Cell, Hobnail, Columnar Cell, and Diffuse Sclerosing, may be associated with a higher risk of the cancer spreading or returning [7][8].
  • NIFTP: This stands for Non-invasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features. It is a “borderline” growth that looks like cancer but does not invade nearby tissue. If a tumor is confirmed as NIFTP (which can only be diagnosed after the entire tumor is surgically removed and examined), it is no longer called “cancer,” and the outlook is excellent with recurrence being exceptionally rare [9][10].

Molecular Markers: The Genetic “Driver”

Your doctor may test the tumor for specific genetic mutations to help predict its behavior:

  • BRAF V600E: Found in about 60% of PTC cases. While common, it is not a perfect predictor of risk on its own [11].
  • TERT Promoter: A mutation that is more concerning, especially when it appears alongside BRAF. This combination is linked to a higher risk of the cancer returning or being resistant to treatment [12][13].
  • RET/PTC: Common in younger patients or those with a history of radiation exposure [14].

The Pathology Report Checklist

After surgery, you will receive a final pathology report. Use this checklist to ensure your report is complete, as these data points determine your follow-up care [15][16]:

  1. Tumor Size: Measured in centimeters (cm).
  2. Margins: Does the cancer reach the edge of the tissue removed? “Clear” or “negative” margins are the goal.
  3. Extrathyroidal Extension (ETE): Did the cancer grow outside the thyroid “capsule” into nearby fat or muscle? Your report must distinguish between microscopic ETE and gross ETE (visible to the surgeon’s naked eye), as gross ETE carries a higher risk [17].
  4. Lymph Node Status: If nodes were removed, how many were tested and how many contained cancer? What was the size of the largest metastatic deposit? [18].
  5. Extranodal Extension: If a lymph node had cancer, did it break through the wall of the node into surrounding tissue? [19].
  6. Lymphovascular Invasion: Was cancer found inside small blood or lymph vessels? [16].
  7. Multifocality: Were there multiple spots of cancer, or just one? [15].

Common questions in this guide

What ultrasound findings can make a thyroid nodule suspicious for PTC?
A nodule may look more suspicious when it is darker than the surrounding thyroid, has irregular or lobulated edges, contains tiny bright spots called microcalcifications, or is taller than it is wide. Radiologists also assess nearby neck lymph nodes for suspicious features.
What do the Bethesda categories on a thyroid biopsy mean?
The Bethesda System summarizes the findings and estimated cancer risk from a fine-needle aspiration. Bethesda I means there were not enough cells, II is usually benign, III and IV are indeterminate, V is suspicious for cancer, and VI indicates a very high certainty of cancer; exact risks vary by institution.
What is NIFTP, and how is it confirmed?
NIFTP is a non-invasive follicular thyroid neoplasm with papillary-like nuclear features that does not invade nearby tissue. It can be confirmed only after the entire tumor is removed and examined, and a confirmed NIFTP is not classified as cancer and generally has an excellent outlook.
Which details should I look for in my thyroid pathology report?
Important details include tumor size, whether the margins are clear, extension beyond the thyroid, and the number and size of involved lymph nodes. The report may also describe extranodal extension, cancer in blood or lymph vessels, and whether there is more than one tumor focus.
What can BRAF, TERT, or RET/PTC results tell me about PTC?
These molecular findings can add information about how papillary thyroid cancer may behave, but no single result determines a person’s outlook by itself. BRAF V600E is common, TERT changes are more concerning especially when combined with BRAF, and RET/PTC is associated with younger patients or a history of radiation exposure.
Do aggressive PTC variants change the risk of recurrence?
Some patterns, including tall-cell, hobnail, columnar-cell, and diffuse-sclerosing variants, may be associated with a higher risk of spread or recurrence than classic PTC. Ask your treating team to explain whether your report identifies one of these patterns and how it affects your follow-up plan.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.My Bethesda category was [X]. What is the estimated risk of malignancy for this specific result at this institution?
  2. 2.Does my pathology report mention any aggressive features like tall-cell or hobnail variants?
  3. 3.Was my tumor completely encapsulated, and does it meet the criteria for NIFTP?
  4. 4.Were my lymph nodes tested, and if so, was there any 'extranodal extension'?
  5. 5.Do we have results for molecular markers like BRAF or TERT, and how do they change my risk assessment?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (19)
  1. 1

    High suspicion US pattern on the ATA guidelines, not cytologic diagnosis, may be a predicting marker of lymph node metastasis in patients with classical papillary thyroid carcinoma.

    Cho E, Kim EK, Moon HJ, et al.

    American journal of surgery 2018; (216(3)):562-566 doi:10.1016/j.amjsurg.2017.12.006.

    PMID: 29268941
  2. 2

    Risk Stratification of Thyroid Nodules with Bethesda III Category: The Experience of a Territorial Healthcare Hospital.

    Al Dawish M, Alwin Robert A, Al Shehri K, et al.

    Cureus 2020; (12(5)):e8202 doi:10.7759/cureus.8202.

    PMID: 32455091
  3. 3

    The 2023 Bethesda System for Reporting Thyroid Cytopathology.

    Ali SZ, Baloch ZW, Cochand-Priollet B, et al.

    Thyroid : official journal of the American Thyroid Association 2023; (33(9)):1039-1044 doi:10.1089/thy.2023.0141.

    PMID: 37427847
  4. 4

    The importance of risk of neoplasm as an outcome in cytologic-histologic correlation studies on thyroid fine needle aspiration.

    Chen YH, Partyka KL, Dougherty R, et al.

    Diagnostic cytopathology 2020; (48(12)):1237-1243 doi:10.1002/dc.24557.

    PMID: 32716614
  5. 5

    Proposal for a novel management of indeterminate thyroid nodules on the basis of cytopathological subclasses.

    Rossi M, Lupo S, Rossi R, et al.

    Endocrine 2017; (57(1)):98-107 doi:10.1007/s12020-016-1105-4.

    PMID: 27623969
  6. 6

    Update on the cytologic features of papillary thyroid carcinoma variants.

    Pusztaszeri M, Auger M

    Diagnostic cytopathology 2017; (45(8)):714-730 doi:10.1002/dc.23703.

    PMID: 28262004
  7. 7

    PROGNOSTIC IMPLICATIONS OF HOBNAIL CELL MORPHOLOGY IN PAPILLARY THYROID CARCINOMA: A CLINICOPATHOLOGICAL ANALYSIS.

    Kayhan Y, Azizova L, Gündüz B, et al.

    Acta endocrinologica (Bucharest, Romania : 2005) 2025; (21(1)):80-90 doi:10.4183/aeb.2025.80.

    PMID: 41798965
  8. 8

    Clinical prognostic risk assessment of different pathological subtypes of papillary thyroid cancer: a systematic review and network meta-analysis.

    Zhao J, Zhang W, Lu D, et al.

    Langenbeck's archives of surgery 2025; (410(1)):251 doi:10.1007/s00423-025-03841-2.

    PMID: 40853492
  9. 9

    Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features: An Evidence-Based Nomenclature Change.

    Jug R, Jiang X

    Pathology research international 2017; (2017()):1057252 doi:10.1155/2017/1057252.

    PMID: 28280647
  10. 10

    Noninvasive follicular thyroid neoplasm with papillary-like nuclear features: a problematic entity.

    Zajkowska K, Kopczyński J, Góźdź S, Kowalska A

    Endocrine connections 2020; (9(3)):R47-R58 doi:10.1530/EC-19-0566.

    PMID: 32061158
  11. 11

    Prognostic Value of BRAF V600E Mutation in Papillary Thyroid Carcinoma: A Meta-Analysis of Nodal Involvement, Distant Metastases, Recurrence, and Mortality.

    Gatta E, Pirola I, Gandossi E, et al.

    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2026; (32(3)):416-426 doi:10.1016/j.eprac.2025.12.003.

    PMID: 41419184
  12. 12

    Mortality Risk Stratification by Combining BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Cancer: Genetic Duet of BRAF and TERT Promoter Mutations in Thyroid Cancer Mortality.

    Liu R, Bishop J, Zhu G, et al.

    JAMA oncology 2017; (3(2)):202-208 doi:10.1001/jamaoncol.2016.3288.

    PMID: 27581851
  13. 13

    Effects of Coexistent BRAFV600E and TERT Promoter Mutations on Poor Clinical Outcomes in Papillary Thyroid Cancer: A Meta-Analysis.

    Moon S, Song YS, Kim YA, et al.

    Thyroid : official journal of the American Thyroid Association 2017; (27(5)):651-660 doi:10.1089/thy.2016.0350.

    PMID: 28181854
  14. 14

    Multi-gene assay and clinical characteristics research in papillary thyroid carcinoma.

    Deng C, Li S, Yang Z, et al.

    Gland surgery 2021; (10(1)):242-251 doi:10.21037/gs-20-589.

    PMID: 33633980
  15. 15

    Critical Prognostic Parameters in the Anatomic Pathology Reporting of Differentiated Follicular Cell-Derived Thyroid Carcinoma.

    Xu B, Ghossein R

    Cancers 2019; (11(8)) doi:10.3390/cancers11081100.

    PMID: 31382401
  16. 16

    Crucial parameters in thyroid carcinoma reporting - challenges, controversies and clinical implications.

    Xu B, Ghossein RA

    Histopathology 2018; (72(1)):32-39 doi:10.1111/his.13335.

    PMID: 28782127
  17. 17

    Data set for reporting carcinoma of the thyroid: recommendations from the International Collaboration on Cancer Reporting.

    Ghossein R, Barletta JA, Bullock M, et al.

    Human pathology 2021; (110()):62-72 doi:10.1016/j.humpath.2020.08.009.

    PMID: 32920035
  18. 18

    Macroscopic extranodal extension is an independent predictor of lung metastasis in papillary thyroid cancer.

    Hei H, Gong W, Zheng C, et al.

    Endocrine 2022; (77(1)):73-79 doi:10.1007/s12020-022-03045-4.

    PMID: 35389141
  19. 19

    Extent of Extrathyroidal Extension as a Significant Predictor of Nodal Metastasis and Extranodal Extension in Patients with Papillary Thyroid Carcinoma.

    Kim JW, Roh JL, Gong G, et al.

    Annals of surgical oncology 2017; (24(2)):460-468 doi:10.1245/s10434-016-5594-4.

    PMID: 27654105

This page is for informational purposes only and does not constitute medical advice. Your thyroid specialist, surgeon, and pathologist should interpret your specific ultrasound, biopsy, and pathology results with you.

Get notified when new evidence is published on thyroid gland papillary carcinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.